



Leptin Antagonist Triple Mutant, PEGylated, human recombinant (rHuLeptin-tm-PEG)

Catalog No: 97318
Lot No: XXXXX
Source: *E. coli*
Synonyms:

Description

Pegylated leptin antagonist triple mutant human recombinant is a single non-glycosylated polypeptide chain containing 146 amino acids and additional Ala at N-terminus and having a molecular weight of 35.6 kDa. Leptin was mutated, resulting in L39A/D40A/F41A. However due to enlarged hydrodynamic volume it runs on the SDS-PAGE as 48 kDa protein and in gel-filtration on Superdex 200 as over 200 kDa protein. Leptin antagonist triple mutant human recombinant is mono-pegylated with 20 kDa PEG and was purified by proprietary chromatographic techniques.

Physical Appearance

White lyophilized (freeze-dried) powder.

Formulation

The protein was lyophilized from a concentrated (0.65 mg/ml) solution with 0.003 mM NaHCO₃.

Solubility

It is recommended to reconstitute the lyophilized leptin antagonist triple mutant pegylated in sterile 0.4% NaHCO₃ adjusted to pH 8-9, not less than 100 µg/ml, which can then be further diluted to other aqueous solutions.

Stability

Lyophilized PEG-SHLA, although stable at room temperature for several weeks, should be stored desiccated below – 20°C. Upon reconstitution at > 0.1 mg/ml and up to 2 mg/ml of PEG-SHLA and filter sterilization mLEP mutant can be stored at 4°C or even room temperature for several weeks making it suitable for long term infusion studies using osmotic pumps. At lower concentration addition of a carrier protein (0.1% HSA or BSA) is suggested. Please prevent freeze-thaw cycles.

Purity

Greater than 98.0% as determined by (a) Gel filtration analysis, (b) Analysis by SDS-PAGE.

Activity

Capable of inhibiting leptin-induced proliferation of BAF/3 cells stably transfected with the long form of human leptin receptor. Its in vitro activity is 6 - 8 fold lower than the non-pegylated antagonist but in vivo it has profound weight gain effect (as compared to the non-pegylated antagonist), resulting mainly from increased food intake. Its in vivo activity compared to that of PEG-MLA is 9 - 27 fold higher.

Usage

This product is offered by Biomol for research purposes only. Not for diagnostic purposes or human use. It may not be resold or used to manufacture commercial products without written approval of Biomol GmbH.

CONTACT US TODAY

BIOMOL GmbH • Kieler Straße 303a • 22525 Hamburg • Germany • info@biomol.de • www.biomol.de

Fon: +49 (0)40-853 260 0 • TOLL FREE IN GERMANY: Fon: 0800-246 66 51